Ocular Therapeutix Inc (OCUL) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $-0.46 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.49. The company posted revenue of $.44 million in the period, compared to analysts expectations of $.55 million. The company’s revenue was down -3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.45 EPS.
Ocular Therapeutix Inc closed down -0.36 points or -5.56% at $6.11 with 27,38,863 shares getting traded on Monday. Post opening the session at $6.62, the shares hit an intraday low of $5.71 and an intraday high of $6.95 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 10, 2016, Amarpreet Sawhney (CEO) purchased 10,000 shares at $6.70 per share price. According to the SEC, on Sep 17, 2015, James Fortune (Chief Operating Officer) sold 9,470 shares at $17.16 per share price. On Mar 6, 2015, Eric Ankerud (officer ) purchased 1,000 shares at $13.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Ocular Therapeutix Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG) which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development such as OTX-DP OTX-TP OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.